# 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

> **NCT00680017** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 280 (actual)

## Conditions studied

- Dyslipidemia
- Kidney Disease

## Interventions

- **DRUG:** ABT-335 plus rosuvastatin
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT00680017
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2012-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00680017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00680017, "30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00680017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*